Pritzker School of Medicine, University of Chicago, Chicago, USA.
Department of Public Health Sciences, University of Chicago, Chicago, USA.
J Gen Intern Med. 2023 Sep;38(12):2662-2670. doi: 10.1007/s11606-023-08249-6. Epub 2023 Jun 20.
The Medicare Bundled Payments for Care Improvement (BPCI) program reimburses 90-day care episodes post-hospitalization. COPD is a leading cause of early readmissions making it a target for value-based payment reform.
Evaluate the financial impact of a COPD BPCI program.
DESIGN, PARTICIPANTS, INTERVENTIONS: A single-site retrospective observational study evaluated the impact of an evidence-based transitions of care program on episode costs and readmission rates, comparing patients hospitalized for COPD exacerbations who received versus those who did not receive the intervention.
Mean episode costs and readmissions.
Between October 2015 and September 2018, 132 received and 161 did not receive the program, respectively. Mean episode costs were below target for six out of eleven quarters for the intervention group, as opposed to only one out of twelve quarters for the control group. Overall, there were non-significant mean savings of $2551 (95% CI: - $811 to $5795) in episode costs relative to target costs for the intervention group, though results varied by index admission diagnosis-related group (DRG); there were additional costs of $4184 per episode for the least-complicated cohort (DRG 192), but savings of $1897 and $1753 for the most complicated index admissions (DRGs 191 and 190, respectively). A significant mean decrease of 0.24 readmissions per episode was observed in 90-day readmission rates for intervention relative to control. Readmissions and hospital discharges to skilled nursing facilities were factors of higher costs (mean increases of $9098 and $17,095 per episode respectively).
Our COPD BPCI program had a non-significant cost-saving effect, although sample size limited study power. The differential impact of the intervention by DRG suggests that targeting interventions to more clinically complex patients could increase the financial impact of the program. Further evaluations are needed to determine if our BPCI program decreased care variation and improved quality of care.
This research was supported by NIH NIA grant #5T35AG029795-12.
医疗保险捆绑支付改善护理(BPCI)计划为住院后 90 天的护理期提供报销。COPD 是导致早期再入院的主要原因,这使其成为基于价值的支付改革的目标。
评估 COPD BPCI 计划的财务影响。
设计、参与者、干预措施:一项单站点回顾性观察性研究评估了基于证据的过渡护理计划对住院治疗 COPD 加重患者的病例成本和再入院率的影响,比较了接受和未接受干预的患者。
平均病例成本和再入院率。
在 2015 年 10 月至 2018 年 9 月期间,分别有 132 名患者接受了该计划,161 名患者未接受该计划。干预组有六个季度的平均病例成本低于目标,而对照组只有一个季度低于目标。总体而言,干预组相对于目标成本,平均病例成本节约了 2551 美元(95%置信区间:-811 至 5795 美元),但结果因索引入院诊断相关组(DRG)而异;对于最不复杂的队列(DRG 192),每个病例的额外成本为 4184 美元,但对于最复杂的索引入院(DRGs 191 和 190),每个病例的节约成本分别为 1897 美元和 1753 美元。在 90 天的再入院率方面,与对照组相比,干预组的平均再入院率下降了 0.24。再入院和医院出院到熟练护理设施是导致成本增加的因素(分别为每个病例增加 9098 美元和 17 美元)。
尽管样本量限制了研究的力度,但我们的 COPD BPCI 计划具有非显著的成本节约效果。干预措施对 DRG 的影响差异表明,针对更具临床复杂性的患者进行干预可能会增加该计划的财务影响。需要进一步评估以确定我们的 BPCI 计划是否降低了护理的变异性并改善了护理质量。
本研究由 NIH NIA 拨款 #5T35AG029795-12 支持。